Clinique Clinical Advanced Clearing Gel: the version behind the participant count

The manufacturer names Clinical Advanced Clearing Gel, describes a hydro-gel, displays a 20 mL presentation and gives 2% salicylic acid. The named posted label connects that Advanced identity to its acne information. Those fields define the reviewed item rather than a broad Clinique acne collection or the separately named older gel. Advanced manufacturer record. Advanced label.

The version-and-label guide explains why a modifier in a product name can matter as much as a familiar brand. An exact identity should precede any comparison of advertised results.

The Advanced record advertises a visible-blemish-size result after one hour. Its footnote attributes that statement to clinical testing on 31 women after one use. The group, period and endpoint stay together. This is not a blackhead or pore endpoint, and it is not a complete clinical report that we independently examined. Advanced claim and footnote. The one-hour period should stay with visible blemish size, rather than becoming the timing attached to every acne or pore statement on the page. Keeping the denominator of 31 women visible also prevents the short result from sounding like a universal promise to everyone who sees the product name.

The study description is reported as evidence context, not a personal instruction. For another market-and-endpoint reading question, the Paula’s Choice review provides a useful comparison route without lending its results to this gel.

The manufacturer’s complete declaration carries ILN52924 and matches the March 2025 NDC 49527-221 label’s inactive list. Its package-change caveat remains important: agreement between the two examined records does not confirm every individual package. The formula identifier helps specify the base being described rather than simply saying that Clinique lists ingredients somewhere. Advanced declaration. Label ingredients. An ILN identifier adds precision to the manufacturer’s ingredient account. It does not independently verify the ingredients in a personal container, but it does let the review name the exact declaration being compared. That is especially useful where the older item has another identifier and another base.

The two-percent comparison keeps active strength separate from a complete preparation. Here, the base and identity are documented more closely, while no finished-batch concentration assay is claimed.

The separate Clinical Clearing Gel record carries ILN52627 and includes an older pore-tightening narrative. Its base is different from the retained Advanced declaration. Those details remain an account of the legacy item; they are not inserted into the Advanced ingredient list or used to complete the Advanced evidence record. Legacy identity and declaration. Dropping Advanced from the name would obscure this separation before the evidence is even discussed. The legacy record can remain available for a historical comparison while still being excluded as a source of the current gel’s participant count, ingredients or promised effect.

The Murad cleanser review offers a distinct historical-list question. The navigation connects similar reading tasks, not product composition or measured outcomes across the two brands.

The legacy record separates a 12-week prescription-comparison headline from a consumer account saying 95% had clearer skin, involving 118 women and two uses overnight. The examined material does not identify a complete comparator and full report for the prescription comparison. These older statements cannot become extra support for the Advanced 31-woman size claim. Older test-summary context. The 118-woman account is described as a consumer result, while the 31-woman Advanced footnote uses clinical-testing language. Those source labels are retained rather than flattened into one total participant number. Adding the groups would invent an analysis that neither manufacturer record supplies.

The differing groups already answer different questions. A prescription reference is not a clinical winner designation. Reporting the older method words is also not an instruction for personal use of either gel.

The posted Advanced label places 2% salicylic acid in its active field and supplies acne-use and caution information. FDA’s Drug Facts explanation separates those fields from inactive ingredients and other label details. That structure helps distinguish formal purpose from a manufacturer’s appearance-study summary. Advanced acne label. FDA label framework.

Neither the formal purpose nor the advertising supplies an individual outcome for a reader. The review does not provide a routine or compatibility assurance. Quantity and fulfillment are different inquiries too, as the supply-term guide explains.

The available records support a clear separation: Advanced identity and ILN52924, its matched acne label and 31-woman visible-size account; then the legacy name, ILN52627 and older result summaries. Their existence does not establish which item a reader holds or what a current order would supply. Advanced formula account. Legacy formula account.

The cached price and notification text are not used as current stock findings. A personal package match, actual delivery and the complete underlying studies remain unexamined. The record comparison can be useful without presenting those missing facts as already settled.